Older adults simultaneously taking beta blockers and trimethoprim-sulfamethoxazole, widely prescribed for urinary tract infections, appeared to be more at risk for hyperkalemia requiring hospitalization than cohorts taking beta blockers and amoxicillin.
Older adults simultaneously taking beta-blockers and trimethoprim-sulfamethoxazole (TMP-SMX), widely prescribed for urinary tract infections, appeared to be more at risk for hyperkalemia requiring hospitalization than their cohorts taking beta-blockers and amoxicillin, according to the results of 2 nested case-control studies out of Canada.
Researchers studied data from a cohort of almost 300,000 adults aged 66 years or older assembled from these studies.
During the study period of 1994 to 2008, 189 patients were hospitalized for hyperkalemia within 2 weeks of receiving a study antibiotic.
Further, the effect was dose-dependent: the higher the dose of TMP-SMX, the greater the risk. No such risk was identified with ciprofloxacin, norfloxacin, or nitrofurantoin.
The study was conducted largely because the researchers surmised that the concurrent use of beta-blockers was the cause of the higher risk of severe hyperkalemia in older TMP-SMX users. However, a similarly increased risk was found among older adults not taking beta-blockers.
Study researchers then concluded that no added risk exists when TMP-SMX is used in combination with beta-blockers.
Weir MA, Juurlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol. 2010. Epub ahead of print.
Study: Plant-based diets lower hypertensive disorders of pregnancy risk
March 28th 2024A recent study suggests that adherence to plant-based diets significantly decreases the risk of developing hypertensive disorders of pregnancy, shedding light on dietary interventions for maternal health.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More